Epitalon peptide: anti-aging claims meet a thin human evidence record.
Epitalon has a real four-amino-acid identity and published laboratory research. The current record does not establish that it extends human lifespan, lengthens telomeres in people, treats insomnia, or has a dependable clinical safety profile. This guide keeps identity, cells, human observations, products, and FDA status separate.
Epitalon is identifiable. Its popular human benefits are not established.
PubChem identifies Epitalon as Ala-Glu-Asp-Gly, formula C14H22N4O9, molecular weight 390.35. FDA separately reviews the free-base and acetate forms and says Epithalamin is a different substance.
FDA found no efficacy publication in patients with insomnia and no clinical study assessing safety in humans. A 2025 telomere paper used human cell lines, not people taking Epitalon. Those distinctions are the center of the evidence record.
Read the Epitalon record in four fields.
This is a sourced status snapshot, not a safety score, treatment recommendation, or seller certification. Each field links back to the detailed record below.
No insomnia efficacy trial
FDA found no published efficacy study in insomnia and no clinical study assessing safety in humans.
Inspect the human evidenceNot clinically established
Cell and melatonin-related observations do not prove longevity, telomere, sleep, or disease outcomes in people.
Audit the popular claimsNo FDA-approved product
PCAC recommended inclusion 7-4-1 for each reviewed form. The committee advice is nonbinding and final FDA action is pending.
Check status and destination routesNo normalized price board
Peptide Local does not publish a like-for-like Epitalon price board because the available records do not support a sufficiently verified market comparison.
Identity, cell findings, human outcomes, trial registration, and authorization answer different questions.
Keeping the lanes separate prevents a real molecule or cell result from turning into an unsupported treatment, longevity, safety, or product claim.
A four-amino-acid peptide with form distinctions
Epitalon is Ala-Glu-Asp-Gly and is also called Epithalon. FDA evaluates Epitalon free base and Epitalon acetate as different bulk drug substances. FDA also warns that Epithalamin is a different substance, so those names and preparations cannot be treated as interchangeable.
Telomere findings exist in cells, not treated people
A 2025 paper reports telomere-length findings in human cell lines. Cell work can support a mechanism hypothesis. It cannot show that taking Epitalon extends a person's telomeres, lifespan, healthspan, sleep quality, or clinical outcomes.
Melatonin observations do not establish insomnia treatment
FDA identified a small sublingual Ala-Glu-Asp-Gly study that measured melatonin and a metabolite, but did not assess sleep outcomes or report safety data. FDA found no efficacy publication in patients with insomnia and no study using the proposed subcutaneous route.
Zero exact-name ClinicalTrials.gov records
The July 21 exact-name search for Epitalon, Epithalon, and Ala-Glu-Asp-Gly returned zero study records. This is a dated registry result, not proof that no human publication exists anywhere, which is why the literature and FDA reviews remain separate evidence lanes.
Committee recommended inclusion, with final FDA action pending
Neither reviewed form is a component of an FDA-approved drug. FDA staff proposed not adding either form to the 503A Bulks List, but PCAC recommended inclusion in separate 7-4-1 votes on July 24. The committee advice is nonbinding and is not a final FDA determination.
What the Epitalon record shows, and what it cannot prove.
Each popular claim is paired with the strongest relevant signal and the exact inference that still fails.
Epitalon reverses aging or extends lifespan
Laboratory, animal, telomere, and pineal-peptide research provides hypotheses that are commonly summarized as anti-aging research.
The cited record does not establish that administered Epitalon extends human lifespan, improves healthspan, prevents age-related disease, or reverses aging.
Epitalon lengthens telomeres
A 2025 in vitro study reported increased telomere length in human cell lines through telomerase upregulation or alternative lengthening activity.
Human cell lines are not human participants. The result does not establish an effective dose, durable whole-body effect, clinical benefit, or safety in people.
Epitalon improves sleep or treats insomnia
FDA identified melatonin-related observations, including a small sublingual study, while the reviewed nomination proposed insomnia as a use.
The small study did not assess sleep outcomes or report safety data, and FDA found no efficacy publication in patients with insomnia.
Epitalon has few or no side effects
Public marketing often infers safety from the peptide's size, endogenous-peptide analogies, or the absence of a familiar adverse-event list.
FDA found no clinical studies assessing safety in humans and identifies unresolved aggregation, impurity, characterization, and immunogenicity concerns.
Epitalon prevents cancer
Longevity and cell-biology literature is sometimes expanded into cancer-prevention language on commercial or secondary pages.
No cited administered-human trial establishes cancer prevention. Telomere biology is complex, and a cell mechanism must not be converted into a prevention recommendation.
Every Epitalon vial represents the studied substance
Epitalon has a defined molecular identity, and an analytical paper identified it in two illegal pharmaceutical preparations.
A name on a label does not prove free base versus acetate, concentration, purity, sterility, stability, aggregation, chain of custody, or equivalence to a study material.
Five records, with the study model kept visible.
Human cells, elderly people, an analytical product test, a trial-registry search, and an FDA synthesis are not equivalent forms of evidence.
Epitalon evidence and safety synthesis
FDA found no insomnia efficacy publication and no clinical study assessing safety in humans, while identifying unresolved product-quality and immunogenicity questions.
Exact Epitalon, Epithalon, and Ala-Glu-Asp-Gly search
Zero exact-name records were returned on July 21, 2026. Registry absence is useful context but is not a complete literature search.
Epitalon and telomere length in human cell lines
The study reports a laboratory telomere signal. It did not administer Epitalon to people or measure lifespan, disease, sleep, function, or adverse events.
Pineal peptides and daily melatonin rhythm
The melatonin-rhythm observation does not establish insomnia treatment, and FDA's identity review requires caution when transferring results among Epitalon, Epithalon, and Epithalamin records.
Epitalon identified in illegal preparations
The paper supports an identity and market-integrity caution. It does not establish therapeutic benefit, routine product equivalence, or safe human use.
The July 24 committee result is recorded, but it is not the final step.
Peptide Local dates each stage so a staff proposal or committee recommendation is not silently reported as an approval, ban, or final decision.
Do not add either Epitalon form
FDA staff proposed not adding Epitalon free base or Epitalon acetate to the 503A Bulks List based on the reviewed record.
Read the briefing →PCAC recommended inclusion
Both form-specific questions received reported 7-4-1 votes. The committee advice is nonbinding and does not itself approve Epitalon or change the 503A Bulks List.
Open the verified vote record →Final FDA determination
FDA can complete its review after considering committee input. The status should change only when the agency publishes the later record.
Track all seven substances →Epitalon access and product status depend on the exact destination.
There is no responsible one-line worldwide verdict. Check the precise substance and product, medicine authorization, prescription and compounding rules, import route, seller or pharmacy status, and destination. The routes below help locate official records without pretending that a generic country page proves Epitalon authorization.
Ten Epitalon questions, answered from the current record.
This is educational reporting, not medical advice, a prescription, a product endorsement, or a use protocol.
What is Epitalon peptide?
Epitalon is a synthetic tetrapeptide with the amino-acid sequence alanine-glutamic acid-aspartic acid-glycine, often written Ala-Glu-Asp-Gly or AEDG. PubChem lists formula C14H22N4O9 and molecular weight 390.35 for the indexed compound. FDA evaluates Epitalon free base and Epitalon acetate as different bulk drug substances and warns that Epithalamin is a different substance, so a short product name does not resolve exact identity or formulation.
What are the proven benefits of Epitalon?
The cited record does not establish a proven clinical benefit for an administered Epitalon product. Laboratory and animal work supports hypotheses involving telomeres, pineal biology, melatonin, and aging-related mechanisms. FDA's insomnia review found no efficacy publication in patients with insomnia, and the cited cell-line telomere paper is not a trial in people. The responsible conclusion is that research signals exist while clinical benefit, dose, durability, and product equivalence remain unresolved.
Does Epitalon lengthen telomeres in people?
A 2025 study reported increased telomere length in human cell lines, which is an in vitro result rather than Epitalon administration to human participants. The study can support a laboratory mechanism hypothesis, but it cannot establish a whole-body telomere effect, longer lifespan, better health, disease prevention, or an effective and safe human dose. A claim about human benefit needs administered-human evidence with clinically meaningful outcomes and adequate follow-up.
Does Epitalon improve sleep or treat insomnia?
FDA evaluated insomnia and found no publication establishing efficacy in patients with insomnia. The review discusses a small sublingual Ala-Glu-Asp-Gly study that measured melatonin and a metabolite, but it did not assess sleep outcomes or report safety data. A change in a hormone marker is not the same as falling asleep faster, sleeping longer, improving daytime function, or demonstrating a favorable benefit-risk profile in a controlled insomnia trial.
Is Epitalon proven to slow aging or extend lifespan?
No administered-human evidence in the cited record establishes that Epitalon slows aging, extends lifespan, improves healthspan, or prevents age-related disease. Cell, animal, telomere, and melatonin findings can motivate research, but they are not substitutes for randomized human trials with clinically meaningful outcomes and sufficient follow-up. The words anti-aging and longevity describe popular hypotheses and marketing claims here, not an established indication or demonstrated human result.
What are the side effects of Epitalon?
A dependable clinical side-effect rate cannot be calculated from the current evidence because FDA found no clinical studies assessing Epitalon safety in humans. Missing adverse-event data is not evidence that adverse events are absent. FDA also identifies unresolved questions involving aggregation, peptide-related impurities, characterization, immunogenicity, formulation, route, and exposure. Those uncertainties are separate from the additional risk that a marketed vial may not match its represented identity or quality.
Is Epitalon FDA approved?
No FDA-approved Epitalon drug is established by the current FDA record. FDA states that neither Epitalon free base nor Epitalon acetate is a component of an FDA-approved drug. FDA staff proposed not adding either form to the 503A Bulks List, but PCAC recommended inclusion in separate 7-4-1 votes on July 24. The committee advice is nonbinding and is not a final FDA decision or drug approval.
Did FDA ban Epitalon?
That is not an accurate description of the dated record. FDA staff proposed that Epitalon free base and Epitalon acetate not be included on the 503A Bulks List, but PCAC recommended inclusion in separate 7-4-1 votes on July 24. FDA can consider the nonbinding committee advice before issuing a final determination. A 503A bulk-substance decision also answers a specific federal compounding question. It is not interchangeable with drug approval, a universal possession rule, or every country's medicine and import law.
What is the correct Epitalon dosage?
There is no FDA-approved Epitalon label or established self-use dosage for the products discussed here. Cell concentrations, animal regimens, a small sublingual research study, a proposed subcutaneous route, seller instructions, and anecdotal cycles involve different forms, formulations, routes, exposures, and evidence standards. They should not be converted into a personal regimen. This guide does not provide reconstitution, injection, dosing, cycling, or stacking instructions for an unapproved substance.
Can you buy Epitalon legally in your country?
A public listing, research-use label, local currency, or international shipping claim cannot decide that. The answer depends on the exact free-base or acetate form, represented product, intended use, medicine authorization, prescription and compounding controls, import route, seller or pharmacy status, and destination. Start with the destination's medicine regulator, customs or import authority, and professional licensing records. A generic country page can provide the route, but it cannot create an Epitalon authorization that the official record does not show.
A molecular identity is not a finished product, proven benefit, or personal regimen.
Epitalon free base, Epitalon acetate, Epithalon, Epithalamin, a cell-culture material, a study intervention, a compounded preparation, and a seller vial can differ in identity, formulation, concentration, impurities, aggregation, sterility, exposure, and risk.
FDA approval, 503A list status, country authorization, import status, seller availability, product authentication, and clinical evidence are separate records. No single source here supplies a personal treatment decision.